Life Biosciences Appoints Seasoned Biopharma Executive Jerry McLaughlin as CEO prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Credit: Albert Einstein College of Medicine
April 22, 2021 (BRONX, NY) Researchers at Albert Einstein College of Medicine have designed an experimental drug that reversed key symptoms of Alzheimer s disease in mice. The drug works by reinvigorating a cellular cleaning mechanism that gets rid of unwanted proteins by digesting and recycling them. The study was published online today in the journal
Cell. Discoveries in mice don t always translate to humans, especially in Alzheimer s disease, said co-study leader Ana Maria Cuervo, M.D., Ph.D., the Robert and Renée Belfer Chair for the Study of Neurodegenerative Diseases, professor of developmental and molecular biology, and co-director of the Institute for Aging Research at Einstein. But we were encouraged to find in our study that the drop-off in cellular cleaning that contributes to Alzheimer s in mice also occurs in people with the disease, suggesting that our drug may also work in humans. In the 1990s, Dr. Cuervo discovered
Share this article
Share this article
BOSTON, April 22, 2021 /PRNewswire/ Life Biosciences, a pioneering life sciences company targeting the biology of aging, today announced the publication of preclinical research demonstrating clinical benefit of its chaperone-mediated autophagy activator platform in mice models of Alzheimer s disease. The article, titled
Cell on April 22, 2021.
Chaperone-mediated autophagy (CMA) controls the levels of soluble proteins in cells. It has been proposed that the age-related decline of CMA leads to an increased concentration of insoluble proteins that may play a role in the pathogenesis of neurodegenerative diseases such as Alzheimer s disease. This study demonstrated that the upregulation of CMA with one of Life Biosciences tool oral compounds significantly improved neurologic function and decreased the accumulation of insoluble protein aggregates in two different mouse models of Alzheimer s disease, even after the onset of neurologic dysfunct